梁虹艺;叶嘉盛;季波;袁进;万宁;
LIANG Hongyi;YE Jiasheng;JI Bo;YUAN Jin;WAN Ning;Department of Clinical Pharmacy ,General Hospital of Southern Theatre Command;

• 1:中国人民解放军南部战区总医院临床药学科

摘要(Abstract)：

目的开展国产和原研注射用盐酸万古霉素治疗甲氧西林耐药金黄色葡萄球菌(MRSA)感染的药物经济学评价,为临床选药提供参考依据,促进合理用药。方法有效率通过课题组前期已发表的《基于PSM法的真实世界中国产与原研注射用盐酸万古霉素疗效和安全性一致性评价的队列研究》获得,筛选明确MRSA感染的90例患者,其中来可信组23例,稳可信组67例。成本只计直接医疗成本,数据来自广州市某三级医院住院患者病例资料。采用决策树模型对国产组和原研组注射用盐酸万古霉素进行成本效果分析,模型结果的稳健性通过单因素敏感性分析来评估。结果来可信组有效率为86.9%,无不良反应发生;稳可信组有效率为85.1%,发生1例不良反应。两组有效率差异无统计学意义(P>0.05)。来可信组期望成本为11 256.47元,稳可信组期望成本为11 723.92元。每使1例患者临床获益,来可信需要的增量药物治疗成本为-25 969.47元。敏感性分析结果显示模型稳健性好。结论来可信比稳可信在治疗MRSA感染时更具有经济性。
OBJECTIVE To carry out the pharmacoeconomic evaluation of domestic and original injection of vancomycin hydrochloride for the treatment of methicillin-resistant staphylococcus aureus(MRSA) infection, and to provide evidence for doctors to choose drugs and promote reasonable medication. METHODS Response rate was obtained from the previously published study entitled “Cohort study on the efficacy and safety of domestic and original vancomycin hydrochloride for injection in real-world based on PSM method”.A total of 90 patients with clear MRSA infection using generic vancomycin(Laikexin group, 23 cases)or original vancomycin(Vancocin group, 67 cases)were included.Only the direct medical cost was recorded in the current study.The data was collected from inpatients in a tertiary hospital in Guangzhou.The decision tree model was used for cost effectiveness analysis of vancomycin hydrochloride in the domestic group and the original research group.The robustness of the model was verified by single factor sensitivity analysis. RESULTS There was no significant difference(P>0.05) between two groups.The response rate of Laikexin group was 86.9% with no one adverse reaction occurring.And the response rate of Vancocin group was 85.1% with adverse reaction occurring in 1 case.The excepted cost of Laikexin and Vancocin were 11 256.47 yuan and 11 723.92 yuan, respectively.The cost of Laikexin for each unit of clinical effect was-25 969.47 yuan less than Vancocin.The results of sensitivity analysis indicated that the study results were robust. CONCLUSION Laikexin is more economical than Vancocin in treating MRSA infections.

关键词(KeyWords)： MRSA;来可信;稳可信;决策树;成本效果
MRSA;Laikexin;Vancocin;decision tree;cost-effectiveness

Abstract:

Keywords:

基金项目(Foundation): 广东省自然科学基金-面上项目(2021A1515012251)

作者(Authors): 梁虹艺;叶嘉盛;季波;袁进;万宁;
LIANG Hongyi;YE Jiasheng;JI Bo;YUAN Jin;WAN Ning;Department of Clinical Pharmacy ,General Hospital of Southern Theatre Command;

参考文献(References)：

• [1] 段思琪，崔莎莎，李月，等.MRSA的耐药机制及防治研究进展[J].国际医药卫生导报，2018,24(10):1464-1466
• [2] Liu C,Bayer A,Cosgrove S E,et al.Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J].Clin Infect Dis,2011,52(3):e18-e55.
• [3] 梁虹艺，万宁，叶嘉盛，等.基于PSM法的真实世界中国产与原研注射用盐酸万古霉素疗效和安全性一致性评价的队列研究[J].中国医院药学杂志，2019,39(17):1751-1754.
• [4] 吴久鸿.药物经济学[M].北京：高等教育出版社，2017.
• [5] 卫红涛，崔向丽，刘莹，等.临床药师开展药物治疗管理的实践经验与成本-效益分析[J].中国现代应用药学，2020,37(15):1884-1888.
• [6] 袁展东.国产与进口厄贝沙坦片治疗原发性高血压的成本-效果观察[J].北方药学，2016,13(6):153-154.
• [7] 中国药学会药物经济学专业委员会.中国药物经济学评价指南(2011版)[J].中国药物经济学，2011(3):6-48.
• [8] 张方，郭莹，李九翔.药物经济学应用与案例[M].北京：化学工业出版社，2018.
• [9] 黄春，莫凡露，秦幸楠，等.运用决策树模型对国产和进口万古霉素治疗耐甲氧西林金黄色葡萄球菌颅内感染进行成本-效果分析[J].中国药房，2019,30(9):1256-1259.
• [10] 史发林，丁丽丽，姚新宝，等.基于决策树模型的抗菌药物治疗鲍曼不动杆菌肺部感染经济学评价[J].中国全科医学，2020,23(8):980-984.
• [11] 范洪伟，李华茵，焦力，等.国产盐酸万古霉素治疗耐药G+球菌感染的有效性和安全性临床研究[J].中国新药杂志，2010,19(5):391-395.
• [12] 唐文明.万古霉素致不良反应42例文献分析[J].抗感染药学，2013,10(4):313-315.
• [13] 邱雄泉，郑乐怡，陈晓坚.万古霉素致不良反应41例文献分析[J].抗感染药学，2017,14(4):804-807.
• [14] 王东晓，朱曼，郭代红，等.930例糖肽类和噁唑烷酮类抗感染药物药品不良反应/事件报告分析[J].中国药物应用与监测，2017,14(1):37-41.
• [15] 蒋荣.39例患者应用万古霉素致不良反应文献分析[J].临床医药文献电子杂志，2018,5(33):160-161.
• [16] 赵春丽，裴航，赵保红，等.95例万古霉素不良反应文献分析[J].中国药物警戒，2018,15(6):354-358.
• [17] Daniel Mullins C,Kuznik A,Shaya F T,et al.Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus[J].Clin Ther,2006,28(8):1184-1198.
• [18] Grau S,Alvarez-Lerma F,del Castillo A,et al.Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain[J].J Chemother,2005,17(2):203-211.
• [19] de Cock E,Krueger W A,Sorensen S,et al.Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany[J].Infection,2009,37(2):123-132.
• [20] Machado A R L,Arns C D C,Follador W,et al.Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus[J].Braz J Infect Dis,2005,9(3):191-200.
• [21] 童向霞.国产与进口万古霉素治疗开颅术后颅内感染的疗效与经济效价比较[J].中国老年学杂志，2012,32(24):5588-5589.
• [22] 朱爱江.两种不同厂家的万古霉素治疗重症G+球菌感染的成本-效果分析[J].天津药学，2004,16(1):46-47.
• [23] 孔晓东.药物经济学：概念、方法和应用[J].国外医学药学分册，1994,21(1):13-18.
• [24] 刘雪丽，郑丽英，宋佳芳，等.心血管病高危及以上风险患者使用氨氯地平阿托伐他汀钙片的成本-效果分析[J].中国药物经济学，2019,14(8):19-25.
• [25] 国家统计局.2018 年国民经济和社会发展统计公报[EB/OL].(2019-02-28)[2019-08-16].http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.htm.